[Setting up haploidentical hematopoietic cell transplantation in low- and middle-income countries: The Recommendations of the Francophone Society of Bone Marrow and Cellular Therapy (SFGM-TC)].

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-10-18 DOI:10.1016/j.bulcan.2024.09.001
Fati Hamzy, Patrice Chevallier, Bénédicte Bruno, Valérie Coiteux, Maria El Kababri, Ahmad Ibrahim, Anas Oudrhiri, Ibrahim Yakoub-Agha, Mohamed-Amine Bekadja
{"title":"[Setting up haploidentical hematopoietic cell transplantation in low- and middle-income countries: The Recommendations of the Francophone Society of Bone Marrow and Cellular Therapy (SFGM-TC)].","authors":"Fati Hamzy, Patrice Chevallier, Bénédicte Bruno, Valérie Coiteux, Maria El Kababri, Ahmad Ibrahim, Anas Oudrhiri, Ibrahim Yakoub-Agha, Mohamed-Amine Bekadja","doi":"10.1016/j.bulcan.2024.09.001","DOIUrl":null,"url":null,"abstract":"<p><p>Nowadays, haploidentical hematopoietic cell transplantation (haplo-HCT) has been routinely used worldwide. However, this procedure is still rarely proposed in low- or middle-income countries. During the 13th annual harmonization workshops of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), a designated working group has proposed recommendations on how to set up such a transplantation in these countries. This was based on a review of the literature and expert-opinion as well as the previously published workshop on haplo-HCT of SFGM-TC (2016). Haploidentical donors appear to be a first alternative to HLA-matched siblings since the access to unrelated donor international registries are limited for several countries. While the procedure has the advantage of immediate access to several potential donors and of low cost, Haplo-HCT should be performed only in centers with a good experience of HLA-matched related transplantation (>10/year). In the absence of an HLA-matched related donor, haplo-HCT should be offered to all patients who are candidate for allo-HCT. Transplantation modalities should follow the conventional procedures with post-transplant cyclophosphamide as GVHD prophylaxis. Conditioning can be myeloablative or not according to each case. Our recommendations are intended to be general in scope and applicable to the majority of allo-HCT centers in these countries. An evaluation at regular basis is needed to assess the feasibility and to improve results.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S146-S156"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin du cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.bulcan.2024.09.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Nowadays, haploidentical hematopoietic cell transplantation (haplo-HCT) has been routinely used worldwide. However, this procedure is still rarely proposed in low- or middle-income countries. During the 13th annual harmonization workshops of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), a designated working group has proposed recommendations on how to set up such a transplantation in these countries. This was based on a review of the literature and expert-opinion as well as the previously published workshop on haplo-HCT of SFGM-TC (2016). Haploidentical donors appear to be a first alternative to HLA-matched siblings since the access to unrelated donor international registries are limited for several countries. While the procedure has the advantage of immediate access to several potential donors and of low cost, Haplo-HCT should be performed only in centers with a good experience of HLA-matched related transplantation (>10/year). In the absence of an HLA-matched related donor, haplo-HCT should be offered to all patients who are candidate for allo-HCT. Transplantation modalities should follow the conventional procedures with post-transplant cyclophosphamide as GVHD prophylaxis. Conditioning can be myeloablative or not according to each case. Our recommendations are intended to be general in scope and applicable to the majority of allo-HCT centers in these countries. An evaluation at regular basis is needed to assess the feasibility and to improve results.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[在中低收入国家开展单倍体造血细胞移植:法语国家骨髓和细胞治疗协会(SFGM-TC)的建议]。
如今,单倍体造血细胞移植(haplo-HCT)已在全球范围内常规使用。然而,在低收入或中等收入国家,这种手术仍很少被提出。在法语国家骨髓移植和细胞治疗协会(SFGM-TC)第 13 届年度协调研讨会上,一个指定工作组就如何在这些国家开展此类移植提出了建议。该建议基于文献综述、专家意见以及 SFGM-TC 先前发布的单倍体-HCT 研讨会(2016 年)。单倍体捐献者似乎是 HLA 匹配同胞的第一选择,因为在一些国家,非亲缘捐献者国际登记处的访问权限有限。虽然该程序具有可立即获得多个潜在供体且费用低廉的优势,但单倍体基因组移植只能在具有丰富 HLA 匹配亲缘移植经验(>10 例/年)的中心进行。在没有 HLA 匹配的相关供体的情况下,应为所有异体肝细胞移植的候选患者提供单倍体肝细胞移植。移植方式应遵循常规程序,移植后使用环磷酰胺作为 GVHD 预防药物。根据每个病例的具体情况,可以进行或不进行骨髓溶解性治疗。我们的建议具有普遍性,适用于这些国家的大多数allo-HCT中心。需要定期进行评估,以评估可行性并改进结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Patient views on continued immune checkpoint inhibition following progression in advanced melanoma: A qualitative study. Identification of immune characteristics of two lung adenocarcinoma subtypes based on immune- and pyroptosis-related genes to improve immunotherapy. [Pediatric aphereses (workshop SFGM-TC)]. [Update for cord blood unit selection in hematopoietic stem cell transplantation (workshop SFGM-TC)]. [Haematopoietic stem cell donation from minor donor: Respecting laws, assessing fitness, delivering information and good care (SFGM-TC)].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1